The company got some bad news to start 2026.

A case targeting alleged fraud around the safety risk of a blockbuster diabetes drug is leveraging the RICO pathway and could ...

This biotech has candidates in late-stage clinical development.

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. | GLP-1 ...

Abivax (ABVX) stock cools as CEO denies talks between Eli Lilly (LLY) and the French government over U.S.-based pharma's ...

The choice isn't that hard.

Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

ONE AFTERNOON in the spring of the year 1910, Ben Lilly with five of his dogs swung off the caboose of a freight train at the ...